Tech Company Financing Transactions
Turnstone Biologics Funding Round
Versant Ventures and private investors participated in a $11.3 million Series A funding round for Turnstone Biologics. The round closed on 10/29/2015.
Transaction Overview
Company Name
Announced On
10/29/2015
Transaction Type
Venture Equity
Amount
$11,300,000
Round
Series A
Investors
Versant Ventures (Lead Investor) (Brad Bolzon)
Proceeds Purpose
This investment enables an aggressive growth strategy to be pursued to fully exploit the commercial potential of the Company's pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
12 York St. 3rd Floor
Ottawa Ontario, K1N 5S6
Canada
Ottawa Ontario, K1N 5S6
Canada
Phone
Website
Email Address
Overview
Turnstone Biologics Inc. is a biotechnology company focused on developing novel oncolytic viral immunotherapies for cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sammy Farah
Chief Financial Officer
Jane Henderson
Vice President
Caroline Breitbach
VP - Human Resources
Kristin Gustafson
VP - Operations
José Otero
VP - R & D
Michael Burgess
VP - R & D
Brian Lichty
Browse more venture capital transactions:
Prev: 10/29/2015: Gobble venture capital transaction
Next: 10/29/2015: Apptuto venture capital transaction
Share this article
News on VC Transactions
We do our best to document every notable VC transaction. VC transactions reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs